NCT05392790Completed
Progressive Resisted Exercise Plus Aerobic Exercise on Osteoporotic Systemic Lupus Erythmatosus
Progressive Resisted Exercise Program Combined with Aerobic Exercise on Osteoporotic Systemic Lupus Erythmatosus Patients, Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 20 Sept 2024
Brief summary (registry, in English)
systemic lupus erythematosus (SLE) is the most common autoimmune disease in women of childbearing age. Promoting physical activity is a major national priority for the general population, including patients with chronic diseases. The aim of this study is to investigate the efficiency of combined effect of progressive resisted exercise with aerobic exercise for bone mineral density, quality of life, muscle strength and physical activity for patients with SLE.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 23 May 2022
- Start date
- 23 May 2022
- Primary completion date
- 30 Oct 2023
- Lead sponsor
- Cairo University
- Diseases
- Lupus (SLE), Osteoporosis
- NCT number
- NCT05392790
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 23 May 2022 to the primary completion date, 30 Oct 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of tobacco; treatment with lipid-lowering, chronotropic or antihypertensive drugs
Other illness
- Patients with active lupus nephritis, cardiovascular dysfunction, rhythm and conduction disorders.
Other
- Those who are pregnant.
- Patients with musculoskeletal disturbances; kidney and pulmonary involvements; peripheral neuropathy and fibromyalgia.
Who the study is looking for
- Diagnosis of systemic lupus erythematosus by the classification criteria ACRa and the 2019 EULARb/ACR Classification Criteria for systemic lupus erythematosus
- Systemic Lupus Erythematosus Disease Activity Index ≥4
- For 30 day prior, stable immunosuppressive therapy with steroid (0-20 mg/day) or other immunosuppressive medication such as hydroxychloroquine, chloroquine, azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, belimumab, rituximab
Age in the registry: 30 years to 50 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nesma Morgan Allam Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.